There are several choices for induction immunosuppression in kidney‐after‐liver transplantation. We used the Scientific Registry of Transplant Recipients database. We assessed all kidney‐after‐liver transplant recipients in the United States b...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O108049270
2021년
-
1527-6465
1527-6473
SCOPUS;SCIE
학술저널
1553-1562 [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
There are several choices for induction immunosuppression in kidney‐after‐liver transplantation. We used the Scientific Registry of Transplant Recipients database. We assessed all kidney‐after‐liver transplant recipients in the United States b...
There are several choices for induction immunosuppression in kidney‐after‐liver transplantation. We used the Scientific Registry of Transplant Recipients database. We assessed all kidney‐after‐liver transplant recipients in the United States between 1/1/2000 and 7/31/2017 to study kidney graft and patient outcomes by induction type. We only included patients discharged on tacrolimus and mycophenolate with or without steroids and had a negative crossmatch before kidney engraftment. We grouped recipients by kidney induction type into the following 3 groups: depletional (n = 550), nondepletional (n = 434), and no antibody induction (n = 144). We studied patient and kidney allograft survival using Cox proportional hazard regression, with transplant center included as a random effect. Models were adjusted for liver induction regimen, recipient and donor age, sex, human leukocyte antigen mismatches, payor type, living donor kidney transplantation, dialysis status, time from liver engraftment, hepatitis C virus status, and the presence of diabetes mellitus at time of kidney transplantation and transplantation year. The 6‐month and 1‐year rejection rates did not differ between groups. Compared with no induction, neither depletional nor nondepletional induction was associated with an improved recipient or graft survival in the multivariable models. Depletional induction at the time of liver transplantation was associated with worse patient survival after kidney transplantation (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.09‐2.67; P = 0.02). Living donor kidney transplantation was associated with a 48.1% improved graft survival (HR, 0.52; 95% CI, 0.33‐0.82; P = 0.00). In conclusion, in the settings of a negative cross‐match and maintenance with tacrolimus and mycophenolate, induction use was not associated with a patient or graft survival benefit in kidney‐after‐liver transplantations.
Post–Liver Transplant Acute Kidney Injury